27 funding - 5,977,793€

data available since 2018

2024

  1. Rational to modulate the Microbiome-induced Endoplasmic Reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

    euro 42,162.00

2023

  1. Rational to modulate the Microbiome and the Microbiome-induced Endoplasmic Reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

    euro 309,592.00

  2. Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC

    euro 100,000.00

  3. Boosting abscopal effect and minimizing locoregional failure by blockade of IL6/STAT3/SMG1 axis in onco-radiotherapy

    euro 150,000.00

  4. Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC

    euro 110,000.00

  5. Epigenetic landscape of immune resistance in pancreatic cancer.

    euro 300,000.00

  6. Integrated Identification of Risk and Screening in Lung Cancer

    euro 10,000.00

2022

  1. ¿Precision medicine for hepatoblastoma: identification of novel therapies and predictive biomarkers using a unique EU biorepository

    euro 180,000.00

  2. Personalising the clinical decision making in ovarian cancer through patient-derived in vitro models.

    euro 150,000.00

  3. Evaluating the therapeutic potential of immunosuppressive paracrine cytokines in the tumor microenvironment of metastatic lesions

    euro 150,000.00

  4. XPRIME, Exploring and exploiting crosspriming in cancer immunotherapy

    euro 299,639.00

2021

  1. Rediseño del impacto de la radioterapia en el cáncer de mama con nuevos actores: Papel de las células tumorales circulantes (CTC) y nuevas vulnerabilidades de base mecanística.

    euro 150,000.00

  2. IL-8/CXCR pathway modulation plus CD137 co-stimulation as a way to overcome resistance to PD-1/PD-L1 pathway blockade in melanoma and kidney cancer patients

    euro 300,000.00

  3. Combinatorial biotherapies for the treatment of pediatric diffuse midline glioma

    euro 300,000.00

  4. Short-term starvation to improve the antitumor activity and attenuate the side effects of lung cancer immunotherapy

    euro 20,000.00

  5. TOWARDS A NEW PARADIGM IN THE TREATMENT OF BLADDER CARCINOMA: THE COMBINATION OF AN EPIGENETIC AGENT AND AN IMMUNE CHECKPOINT INHIBITOR

    euro 180,000.00

2020

  1. Rational gene signature-based drug combinations for lung cancer treatment

    euro 300,000.00

  2. Combinatorial Immunotherapies in a novel GEMM platform for sarcomas: Identification of Therapeutic Efficacy and anticipating Adverse Events

    euro 300,000.00

  3. New Epigenetic Approaches For The Treatment of Liver and Digestive Tumors

    euro 300,000.00

  4. Personalized Planning in RadioTherapy Through Integrative Modeling of Local Dose Effect and New Dosimetric Constraints

    euro 90,000.00